Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | REN | P00797 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21484361 | 0.81 | SSTR4 (0.41) | SSTR4 | |
| SCHEMBL5948132 | 0.81 | SSTR4 (0.41) | SSTR4SLC6A2SLC6A4 | |
| SCHEMBL6937389 | 0.81 | SSTR4 (0.43) | SSTR4SLC6A3 | |
| SCHEMBL3742282 | 0.80 | SSTR4 (0.45) | SSTR4KMT2ARENSLC6A2SLC6A4 | |
| SCHEMBL8292968 | 0.80 | SSTR4 (0.45) | SSTR4KMT2ARENSLC6A2SLC6A4 | |
| SCHEMBL28109125 | 0.80 | REN (0.47) | HPGDALDH1A1SSTR4NPC1KMT2A | |
| SCHEMBL2983183 | 0.80 | ALDH1A1 (0.42) | ALDH1A1SSTR4SMN1; SMN2REN | |
| Hydrochloric Acid SCHEMBL4031709 | 0.79 | SSTR4 (0.44) | SSTR4RENSLC6A2SLC6A4 | |
| SCHEMBL1662913 | 0.78 | ALDH1A1 (0.40) | ALDH1A1SSTR4REN | |
| SCHEMBL7276192 | 0.78 | CTSC (0.41) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784295-B2 | CARRIED OUT IN THE PRESENCE OF AN INORGANIC BASE OR ORGANIC NITROGEN BASE AND A PALLADIUM COMPLEX CATALYST CONTAINING SECONDARY MONOPHOSPHINES WITH ALIPHATIC, BRANCHED OR CYCLIC SUBSTITUENTS AS LIGANDS | SOLVIAS AG (CH) | 2004-08-31 | — | — | US | disclosed |
| US-20030181688-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | INDOLESE ADRIANO (CH) | 2003-09-25 | — | — | US | disclosed |
| EP-1132361-B1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | SOLVIAS AG (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-6548684-B2 | Using monophosphine palladium complex catalyst | SOLVIAS AG (SE) | 2003-04-15 | — | — | US | disclosed |
| US-20010037042-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | SOLVIAS AG (CH) | 2001-11-01 | — | — | US | disclosed |
| EP-1132361-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | Solvias AG (CH) | 2001-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010037042-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | ADH1C, ALKBH3, PNMT | HPGD 1225/4885ALDH1A1 1512/4885MAPT 2841/4885 |
| US-20030181688-A1 | Coupling of nucleophiles, vinyl compounds or CO with water, alcohols or amines to organic compounds | ADH1C, ALKBH3, PNMT | HPGD 1225/4885ALDH1A1 1512/4885MAPT 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.